Industry / Canada
Biovail Restructures Operations
May 2008 | Company News AlertFollowing disappointing financial results, Canadian firm Biovail has revealed a restructuring plan. The drugmaker will close two foreign manufacturing plants and will increasingly focus on developing drugs for the treatment of central nervous system (CNS) disorders. BMI believes that the company has made a necessary change in strategy, but we are most impressed by Biovail's desire to finally end controversy surrounding alleged commercial misconduct during the early 2000s, which has been a significant drain on
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
